clinical trial · NCT03997786
A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis
Moderate-to-severe Chronic Plaque PsoriasisTildrakizumabPlaceboTildrakizumabTildrakizumabTildrakizumabEtanerceptPlacebo
brief summary
The study has been designed with three components. Part A is an open label PK study followed by a randomized trial component (Part B) followed by open label Long Term Extension (LTE). The initial PK analysis is first done in adolescent subjects (12 to \<18 years) before initiating the PK study in younger cohort (6 to \<12 years)
started
Jan 15, 2020
primary completion
Apr 7, 2025
completion
Aug 5, 2031
last updated
Apr 15, 2026
official title
A Multicenter, Randomized, Placebo and Active Comparator-controlled Clinical Trial to Study the Efficacy, Safety and Pharmacokinetics (PK) of Tildrakizumab in Pediatric Subjects From 6 to <18 Years of Age With Moderate to Severe Chronic Plaque Psoriasis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol